Brinker Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Brinker Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,224	Closed	-$384K	–	997
2018 Q2	$384K	Buy	9,224 +579	+7%	+$25.7K	0.01%	792
2018 Q1	$381K	Buy	8,645 +449	+5%	+$22.8K	0.01%	801
2017 Q4	$412K	Sell	8,196 -277	-3%	-$15.2K	0.02%	753
2017 Q3	$430K	Buy	+8,473	New	+$444K	0.02%	712
2017 Q2	–	Sell	-8,242	Closed	-$331K	–	767
2017 Q1	$331K	Buy	8,242 +592	+8%	+$26.6K	0.02%	750
2016 Q4	$366K	Buy	+7,650	New	+$303K	0.02%	523

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Brinker Capital's IONS Position: Q3 2018 in Review

Brinker Capital sold out of Ionis Pharmaceuticals (IONS) in Q3 2018, closing a stake of 9,224 shares — an estimated $384K sold.

Brinker Capital first reported a position in IONS in Q4 2016 and held it in 6 quarters. The position peaked at $430K in Q3 2017. 322 funds tracked by Wall St. Rank hold IONS as of Q3 2018.

Brinker Capital reported no remaining Ionis Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Brinker Capital sold 9,224 Ionis Pharmaceuticals shares in Q3 2018, an estimated $384K.
Brinker Capital first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 6 quarters.
Brinker Capital's Ionis Pharmaceuticals position peaked at $430K in Q3 2017.
322 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2018.

Based on Brinker Capital's 13F filing for Q3 2018, filed 13 Nov 2018.